Evolus Inc (NASDAQ:EOLS) shot up 5.3% on Monday . The stock traded as high as $15.00 and last traded at $14.79, 520,992 shares were traded during mid-day trading. A decline of 43% from the average session volume of 918,632 shares. The stock had previously closed at $14.05.

Several research firms have weighed in on EOLS. Mizuho set a $31.00 target price on Evolus and gave the company a “buy” rating in a research report on Monday, May 20th. Stifel Nicolaus set a $33.00 target price on Evolus and gave the company a “buy” rating in a research report on Wednesday, July 31st. JMP Securities dropped their target price on Evolus from $35.00 to $30.00 and set a “market outperform” rating for the company in a research report on Tuesday, August 13th. They noted that the move was a valuation call. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $35.00 target price on shares of Evolus in a research report on Tuesday, April 30th. Finally, Zacks Investment Research downgraded Evolus from a “hold” rating to a “sell” rating in a research report on Thursday, August 15th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. Evolus has a consensus rating of “Buy” and an average price target of $26.78.

The firm has a 50 day moving average price of $16.51 and a 200-day moving average price of $20.37. The company has a current ratio of 5.01, a quick ratio of 4.51 and a debt-to-equity ratio of 1.87. The firm has a market cap of $385.31 million, a PE ratio of -9.64 and a beta of 4.80.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Monday, August 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.41). The firm had revenue of $2.30 million during the quarter, compared to analyst estimates of $0.29 million. Equities analysts forecast that Evolus Inc will post -3.43 earnings per share for the current fiscal year.

In related news, Director Kristine Romine acquired 2,090 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The stock was acquired at an average price of $14.77 per share, for a total transaction of $30,869.30. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David N. Gill acquired 2,000 shares of the firm’s stock in a transaction dated Thursday, June 13th. The stock was bought at an average price of $13.65 per share, with a total value of $27,300.00. The disclosure for this purchase can be found here. Insiders bought a total of 1,302,791 shares of company stock valued at $25,058,164 in the last quarter. Company insiders own 3.90% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Patriot Financial Group Insurance Agency LLC lifted its stake in Evolus by 50.0% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 1,500 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares during the last quarter. Meeder Asset Management Inc. lifted its stake in Evolus by 48.9% during the first quarter. Meeder Asset Management Inc. now owns 1,732 shares of the company’s stock worth $39,000 after purchasing an additional 569 shares during the last quarter. GSA Capital Partners LLP lifted its stake in Evolus by 7.5% during the second quarter. GSA Capital Partners LLP now owns 18,467 shares of the company’s stock worth $270,000 after purchasing an additional 1,295 shares during the last quarter. Pearl River Capital LLC lifted its stake in Evolus by 217.7% during the first quarter. Pearl River Capital LLC now owns 1,906 shares of the company’s stock worth $44,000 after purchasing an additional 1,306 shares during the last quarter. Finally, Janney Montgomery Scott LLC lifted its stake in Evolus by 7.7% during the second quarter. Janney Montgomery Scott LLC now owns 24,600 shares of the company’s stock worth $360,000 after purchasing an additional 1,750 shares during the last quarter. Institutional investors and hedge funds own 15.54% of the company’s stock.

Evolus Company Profile (NASDAQ:EOLS)

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Recommended Story: Market Timing

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.